Digistain is delivering a radically faster cancer treatment decision-making solution for physicians and patients – reducing costs and actionable treatment decision time, saving up to 30% of unnecessary chemo therapies.
The solution is cleared by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Digistain is a patented risk profiling test for hormone receptor-positive breast cancer patients.
Digistain is a cancer diagnostics company combining advanced and validated techniques with machine learning methods to deliver radically faster breast cancer treatment decision-making data for physicians and patients, reducing informed actionable treatment decision times (time to treatment) from months and weeks to days and hours – all at a dramatically lower cost.
Currently, the company provides a solution for breast cancer and is in the process of developing new solutions for other cancer types.
Learn more at digistain.co.uk
